Minerva Neurosciences, Inc. NERV Open Minerva Neurosciences, Inc. in new tab
Minerva Neurosciences, Inc. Analysis (NERV)
Is Minerva Neurosciences, Inc. a good investment? Minerva Neurosciences, Inc. (NERV) is currently trading at 4.74 USD. Market analysts have a consensus price target of 9.50 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 2.65. This relatively low multiple may signal that Minerva Neurosciences, Inc. is undervalued compared to historical market norms.
Earnings Schedule: Minerva Neurosciences, Inc. is expected to release its next earnings report on Aug. 13, 2026. The market consensus estimate for Forward EPS is -0.48.
Investor FAQ
Does Minerva Neurosciences, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Minerva Neurosciences, Inc.?
Minerva Neurosciences, Inc. is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be Aug. 13, 2026. The company currently has a trailing EPS of -37.03.
Company Profile
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Dividends
Historical Split Corporate Actions
| Split Date | Split Ratio to 1 |
|---|---|
| June 21, 2022 | 0.130000 |
Explore Premium Features
Unlock detailed news and exclusive insights with our Premium subscription.
See Pricing Plans
Community Discussion